BACKGROUND: Several cohort studies in populations without coronary heart disease have demonstrated that up to 40% of incident myocardial infarctions are clinically unrecognized. OBJECTIVE: To determine the incidence of unrecognized myocardial infarction in women with coronary heart disease in the Heart and Estrogen/progestin Replacement Study (HERS). DESIGN: Randomized, double-blind, placebo-controlled trial of conjugated estrogens plus medroxyprogesterone or identical placebo with 4.1 years of follow-up. SETTINGS: Outpatient and community settings at 20 U.S. clinical centers. PATIENTS: 2763 postmenopausal women younger than 80 years of age with coronary heart disease and an intact uterus. MEASUREMENTS: Annual electrocardiograms were obtained for all participants during follow-up (mean, 4.1 years) and were evaluated by using the NOVACODE computer algorithm and visual confirmation. A total of 13 715 electrocardiograms were obtained. Suspected unrecognized myocardial infarctions were investigated by comparing a participant's previous surveillance electrocardiograms with the electrocardiograms obtained from all of her intervening hospitalizations. Characteristics of patients with recognized and unrecognized myocardial infarction were compared. RESULTS: Among the 256 nonfatal myocardial infarctions, 11 were unrecognized (4.3% [95% CI, 2.2% to 7.6%]). Seven occurred in women assigned to placebo and 4 occurred in women assigned to hormone therapy (P > 0.2). Women with unrecognized myocardial infarction were less likely to have diabetes mellitus or previous angina and were more likely to have had previous bypass surgery compared with women who had clinically recognized myocardial infarction. CONCLUSION: The incidence of unrecognized myocardial infarction in women with coronary disease was far lower than that observed in previous studies of populations without coronary heart disease.
RCT Entities:
BACKGROUND: Several cohort studies in populations without coronary heart disease have demonstrated that up to 40% of incident myocardial infarctions are clinically unrecognized. OBJECTIVE: To determine the incidence of unrecognized myocardial infarction in women with coronary heart disease in the Heart and Estrogen/progestin Replacement Study (HERS). DESIGN: Randomized, double-blind, placebo-controlled trial of conjugated estrogens plus medroxyprogesterone or identical placebo with 4.1 years of follow-up. SETTINGS: Outpatient and community settings at 20 U.S. clinical centers. PATIENTS: 2763 postmenopausal women younger than 80 years of age with coronary heart disease and an intact uterus. MEASUREMENTS: Annual electrocardiograms were obtained for all participants during follow-up (mean, 4.1 years) and were evaluated by using the NOVACODE computer algorithm and visual confirmation. A total of 13 715 electrocardiograms were obtained. Suspected unrecognized myocardial infarctions were investigated by comparing a participant's previous surveillance electrocardiograms with the electrocardiograms obtained from all of her intervening hospitalizations. Characteristics of patients with recognized and unrecognized myocardial infarction were compared. RESULTS: Among the 256 nonfatal myocardial infarctions, 11 were unrecognized (4.3% [95% CI, 2.2% to 7.6%]). Seven occurred in women assigned to placebo and 4 occurred in women assigned to hormone therapy (P > 0.2). Women with unrecognized myocardial infarction were less likely to have diabetes mellitus or previous angina and were more likely to have had previous bypass surgery compared with women who had clinically recognized myocardial infarction. CONCLUSION: The incidence of unrecognized myocardial infarction in women with coronary disease was far lower than that observed in previous studies of populations without coronary heart disease.
Authors: Khawaja Afzal Ammar; Barbara P Yawn; Lynn Urban; Douglas W Mahoney; Jan A Kors; Steven Jacobsen; Richard J Rodeheffer Journal: Ann Noninvasive Electrocardiol Date: 2005-04 Impact factor: 1.468
Authors: Zhu-Ming Zhang; Pentti M Rautaharju; Ronald J Prineas; Carlos J Rodriguez; Laura Loehr; Wayne D Rosamond; Dalane Kitzman; David Couper; Elsayed Z Soliman Journal: Circulation Date: 2016-05-16 Impact factor: 29.690
Authors: Jan Smid; Maximilian Scherner; Oliver Wolfram; Thomas Groscheck; Jens Wippermann; Rüdiger C Braun-Dullaeus Journal: Dtsch Arztebl Int Date: 2018-03-23 Impact factor: 5.594
Authors: Karen G Ordovas; Lauren A Baldassarre; Chiara Bucciarelli-Ducci; James Carr; Juliano Lara Fernandes; Vanessa M Ferreira; Luba Frank; Sophie Mavrogeni; Ntobeko Ntusi; Ellen Ostenfeld; Purvi Parwani; Alessia Pepe; Subha V Raman; Hajime Sakuma; Jeanette Schulz-Menger; Lilia M Sierra-Galan; Anne Marie Valente; Monvadi B Srichai Journal: J Cardiovasc Magn Reson Date: 2021-05-10 Impact factor: 5.364
Authors: M Yldau van der Ende; Luis Eduardo Juarez-Orozco; Ingmar Waardenburg; Erik Lipsic; Remco A J Schurer; Hindrik W van der Werf; Emelia J Benjamin; Dirk Jan van Veldhuisen; Harold Snieder; Pim van der Harst Journal: J Am Heart Assoc Date: 2020-06-23 Impact factor: 5.501
Authors: Alexandra V Rose; Kevin F Boreskie; Jacqueline L Hay; Liam Thompson; Rakesh C Arora; Todd A Duhamel Journal: BMJ Open Date: 2021-05-25 Impact factor: 2.692